Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex & ORCID
Ole Kleist Jeppesen
ResearcherPublications, citations & collaboration network
Ole Kleist Jeppesen is a researcher indexed in ScholarIQ from OpenAlex & ORCID. ScholarIQ records 53 works, 5,587 citations, an h-index of 15 and an i10-index of 16.
53
Works
5,587
Citations
15
h-index
16
i10-index
IDs:OpenAlex
How has Ole Kleist Jeppesen's publication output changed over time?
ScholarIQpublication output · 2009–2026
Output grew100% over the shown period — from 1 works in 2009 to 2 in 2026.
1
1
2
1
1
1
2
1
2
200920182019202020212022202420252026
What are the most-cited papers on Ole Kleist Jeppesen?
ScholarIQmost cited works
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain
New England Journal of Medicine. 20191,969 CitationsOPEN ACCESS
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Melanie J. Davies, Louise Færch, Ole Kleist Jeppesen, Arash Pakseresht, Sue D. Pedersen, Leigh Perreault, Julio Rosenstock, Iichiro Shimomura, Adie Viljoen, Thomas A. Wadden, Ildiko Lingvay
The Lancet. 20211,336 CitationsOPEN ACCESS
Once-Weekly Semaglutide in Adolescents with Obesity
Daniel Weghuber, Timothy Barrett, Margarita Barrientos‐Pérez, Inge Gies, Dan Hesse, Ole Kleist Jeppesen, Aaron S. Kelly, Lucy D. Mastrandrea, Rasmus Sørrig, Silva Arslanian
New England Journal of Medicine. 2022667 CitationsOPEN ACCESS
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Vanita R. Aroda, Julio Rosenstock, Yasuo Terauchi, Yüksel Altuntaş, Nebojsa M. Lalic, Enrique C. Morales Villegas, Ole Kleist Jeppesen, Erik Christiansen, CHRISTIN L. HERTZ, Martin Haluzı́k, PIONEER 1 Investigators, Krim Belkacem, Nabil Chiali, Samia Bourezane, R. Guermaz, P Popivanov, Ivaylo Lefterov, Tsvetalina Tankova, I Penchev, Martina Košková, Miroslava Hudcova, Alica Vesela, Anna Rancova, Martin Haluzı́k, Arihiro Kiyosue, Osamu Matsuoka, Satoshi Inoue, Yasuo Terauchi, Yasushi Fukushima, Yumiko Ide, R. Ortiz, Enrique Villegas, Albina Golovach, Diana Alpenidze, Elena Frolova, Elena Zhdanova, Ludmila Ruyatkina, О. Б. Ершова, Ю. Г. Самойлова, S. T. Zyangirova, Katarina Lalić, Nebojša Lalić, Teodora Beljić Živković, Hayriye Esra Ataoğlu, Okan Bakıner, A. D. Dayan, Mehmet Sargın, Meral Mert, Mine Adaş, Ömür Tabak, Yüksel Altuntaş, Alexander V. Murray, Ali Iranmanesh, Aron Schlau, Bram Wieskopf, Brian D. Snyder, Carl J. Griffin, Charles Fogarty, Charles Lovell, Dale Allison, David Fitzpatrick, David Grant, David C. Klonoff, Dwayne Williams, Eddie Armas, Eileen M. Palace, Gary Ruoff, Gilbert Martinez, Gilberto Perez, Harold Bays, Horia Tatu, James Maynard, Jeanne-Elyse Cedeno, Vanita R. Aroda, Jean Park, Jennefer Sutton, Joe Pouzar, John Bertsch, Jonathan Condit, Jorge Serje, Josel Cabaccan, Joseph Risser, Juan P. Frías, Julio Rosenstock, Kanagaratnam Sivalingam, Kelli Maw, Lenita Hanson, Liana K. Billings, Lisa Connery, Mario Juarez, Michael Lillestol, Neil Fraser, Paul Beckett, Ralph Wade, Raul Gaona, Richard F. W. Jackson, Robert DeLuca, Sady Alpizar, Sharon J. Herring, Stanley Stringam
Diabetes Care. 2019475 CitationsOPEN ACCESS
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Donna H. Ryan, Ildiko Lingvay, John Deanfield, Steven E. Kahn, Eric Barros, Bartolomé Burguera, Helen M. Colhoun, Cíntia Cercato, Dror Dicker, Deborah B. Horn, G. Kees Hovingh, Ole Kleist Jeppesen, Alexander Kokkinos, A. Michael Lincoff, Sebastian M. Meyhöfer, Tuğçe Kalaycı Oral, Jorge Plutzky, André P. van Beek, John Wilding, Robert F. Kushner
Nature Medicine. 2024317 CitationsOPEN ACCESS
Related on ScholarIQ
Novo Nordisk (Denmark)
Institution
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Paper
Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
Paper
Once-Weekly Semaglutide in Adolescents with Obesity
Paper
PIONEER 1: Randomized Clinical Trial of the Efficacy and Safety of Oral Semaglutide Monotherapy in Comparison With Placebo in Patients With Type 2 Diabetes
Paper
Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial
Paper